| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VIROL.2015.09.015 |
| P698 | PubMed publication ID | 26761396 |
| P2093 | author name string | Li Wang | |
| Jianjun Chen | |||
| Richard W Compans | |||
| Bao-Zhong Wang | |||
| Andrei N Vzorov | |||
| P2860 | cites work | A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants | Q27731470 |
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. | Q30374995 | ||
| Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity | Q30399285 | ||
| Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility | Q33323199 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques | Q33683203 | ||
| HIV neutralizing antibodies: clinical correlates and implications for vaccines | Q33703451 | ||
| Which Antibody Functions are Important for an HIV Vaccine? | Q33772637 | ||
| Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization | Q33873610 | ||
| Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail | Q33984243 | ||
| Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine | Q34118124 | ||
| Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein | Q34332519 | ||
| Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. | Q34361680 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant | Q34576055 | ||
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
| HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo | Q35082880 | ||
| Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures | Q35105223 | ||
| A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene | Q35110976 | ||
| Activation of a paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic tail | Q35315674 | ||
| Effects of stabilization of the gp41 cytoplasmic domain on fusion activity and infectivity of SIVmac239. | Q35508285 | ||
| Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles | Q36099235 | ||
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | Q36363231 | ||
| Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. | Q36634800 | ||
| Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells | Q36646920 | ||
| Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection | Q36673306 | ||
| Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses | Q36693991 | ||
| Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1 | Q36760169 | ||
| Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice | Q37101184 | ||
| Truncation of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein defines elements required for fusion, incorporation, and infectivity | Q37410656 | ||
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Q37519312 | ||
| Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains | Q37547162 | ||
| Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain | Q37683010 | ||
| Assembly and release of SIV env proteins with full-length or truncated cytoplasmic domains | Q38356199 | ||
| Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens | Q38581943 | ||
| HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes | Q39402539 | ||
| A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure | Q39588870 | ||
| Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 | Q39612212 | ||
| Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity | Q39880154 | ||
| The rational design of an AIDS vaccine | Q40348550 | ||
| Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity. | Q40468605 | ||
| HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein | Q41138686 | ||
| Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission | Q47878972 | ||
| Selection of recombinant vaccinia viruses on the basis of plaque formation | Q71866680 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 141-150 | |
| P577 | publication date | 2016-01-04 | |
| P1433 | published in | Virology | Q7934867 |
| P1476 | title | Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines | |
| P478 | volume | 489 |
| Q38753959 | "Cytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Env". |
| Q91608895 | Cytoplasmic R-peptide of murine leukemia virus envelope protein negatively regulates its interaction with the cell surface receptor |
| Q38817990 | Dense Array of Spikes on HIV-1 Virion Particles |
| Q89511484 | Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles |
| Q40354961 | Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen |
| Q54207383 | Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies. |
| Q58542579 | Universal influenza vaccines: from viruses to nanoparticles |
Search more.